Takeda Oncology
Michael Curley is a seasoned professional in the biotechnology and oncology fields, currently serving as Senior Director and Global Program Lead for Cell Therapy at Takeda Oncology since January 2017. With a robust background in cell therapy innovation, Curley has overseen the development and execution strategies for gamma delta cell therapy and allogeneic cord blood NK cell therapy. Prior roles at Takeda include leadership positions in I-O Biology and significant contributions to early Discovery programs. Curley's previous experience includes a Senior Scientist role at Merrimack Pharmaceuticals, where strategic priorities for MM-141 research were established. Additionally, research efforts at Massachusetts General Hospital and Joslin Diabetes Center focused on optimizing cancer models and characterizing tumor-initiating cells. Michael Curley holds a PhD in Biochemistry and a B.S. in Biotechnology from the University of Galway.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.